The humoral immune responses to IBV proteins.

Similar documents
Biotechnology-Based Vaccines. Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:

RECOMBINANT VACCINES Live or Killed

Research Update: Avian Disease & Oncology Lab (ADOL) and SEPRL Endemic Poultry Virus Diseases (EPVD)

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors


Overview: Chapter 19 Viruses: A Borrowed Life

Gene Vaccine Dr. Sina Soleimani

Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

Correlation of humoral and cellular immune responses induced by different IBV vaccination regime with the protection afforded against IBV Q1

Worldwide perspective on Infectious Bronchitis. Ruth Bouwstra, DVM, PhD Turkey February 2017

C E E Z A D. Rational Development of Influenza Vaccines: NDV-based influenza vaccines for poultry and livestock

Infectious Bronchitis: how to maximize cross-protection. GD Animal Health - The Netherlands

Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY. Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p.

Interaction of Gumboro and other Immunosuppressive Diseases on Respiratory Disease

Coronaviruses cause acute, mild upper respiratory infection (common cold).

Revision of the RVF chapter in the OIE Terrestrial Manuel D.Goovaerts, IFAH. Mombasa, November 14 th 2012

Suggestions to prevent / control Respiratory Disease Complex in poultry

Objective 3. Develop new and improved diagnostic tools, vaccines, and novel management approaches

Trends in vaccinology

numbe r Done by Corrected by Doctor

Patricia Fitzgerald-Bocarsly

INFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE

Lecture 2: Virology. I. Background

Immunogenicity of Avian Influenza H7N9 Virus in Birds

Advanced Biotechnology in the Development of Novel Vaccines against Major Farm Animal Infectious Diseases in China

24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013

Department of Veterinary Pathology, University of Liverpool, Leahurst Campus, Neston, South Wirral, CH64 7TE, UNITED KINGDOM

A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire.

ESSENTIAL PROTECTION

Viral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص

3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.

Graduated from Kyoto University, Graduate School of Agriculture, Japan M.S degree on Molecular Biology and Microbiology.

Laboratory Diagnosis of Avian Influenza and Newcastle Disease

Influenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics

I. Bacteria II. Viruses including HIV. Domain Bacteria Characteristics. 5. Cell wall present in many species. 6. Reproduction by binary fission

Studying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID

Viral structure م.م رنا مشعل

VACCINE ENGINEERING Dr.T.V.Rao MD

Human Influenza. Dr. Sina Soleimani. Human Viral Vaccine Quality Control 89/2/29. November 2, 2011 HVVQC ١

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

The Journal of Veterinary Medical Science

LEC 2, Medical biology, Theory, prepared by Dr. AYAT ALI

Dr. Ahmed K. Ali Attachment and entry of viruses into cells

Rift Valley Fever Virus: Diagnosis and Vaccines. M. Kariuki Njenga, BVM, PhD Centers for Disease Control and Prevention Nairobi, Kenya

Introduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.

Corporation obtaining approval, the name of its representative, and the address of its main office

Immunization. Immunization procedure called vaccination and the immunizing agent called vaccine (or serum in historical references)

7.012 Problem Set 6 Solutions

Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses

Clinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY

An outbreak of a respiratory infection of multi-agents occurred in poultry flocks in Tripoli, Libya

Influenza or flu is a

MOLECULAR DIVERSITY, EVOLUTIONARY TRENDS, AND MUTATION RATES IN AVIAN CORONAVIRUS INFECTIOUS BRONCHITIS VIRUS ENID THANNA MCKINLEY

EVALUATION OF SINDBIS-M2E VIRUS VECTOR AS A UNIVERSAL INFLUENZA A VACCINE. A Thesis CHRISTINE NGUYEN VUONG

Nanoparticulate Vaccine Design: The VesiVax System

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics

Human Immunodeficiency Virus

Cover Page. The handle holds various files of this Leiden University dissertation

Unit 5 The Human Immune Response to Infection

Application of Reverse Genetics to Influenza Vaccine Development

Development of a VP6 subunit rotavirus vaccine A dual role of VP6 as a vaccine antigen and an adjuvant

Getting the Most Out of Baculovirus. Linda Lua

Avian influenza and pandemic threats

Laboratory tools for monitoring and understanding IBDV infection and vaccination

ORTHOMYXOVIRUSES INFLUENZA VIRUSES. (A,B and C)

Fayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia

Target Design and Immunogenicity

STRUCTURE, GENERAL CHARACTERISTICS AND REPRODUCTION OF VIRUSES

8/13/2009. Diseases. Disease. Pathogens. Domain Bacteria Characteristics. Bacteria Shapes. Domain Bacteria Characteristics

Coronaviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC

H5N1 and H7 LAIV-IAV Prime-Boost Studies

VIRUSES. 1. Describe the structure of a virus by completing the following chart.

3. Antibody to PPRS Virus (PRRSV) 4. Antibody to Pseudorabies Virus /gpl Aujeszky s Disease (PRV/ADV gpl) 5. Antibody to Swine Salmonella

New Technology in Vaccine Engineering

19/06/2013. Viruses are not organisms (do not belong to any kingdom). Viruses are not made of cells, have no cytoplasm, and no membranes.

Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP

Oxford Expression Technologies Ltd

Poultry Disease Manual Characteristics And

MedChem 401~ Retroviridae. Retroviridae

Combinatorial Vaccines for AIDS and other Infectious Diseases

Name Section Problem Set 6

Virus-like particle vaccine activates and promotes B cell differentiation to IgG2a producing plasma cells Qizhi Cathy Yao, M.D., Ph.D.

ASEAN STANDARDS FOR ANIMAL VACCINES

Immunological aspects of the efficiency of protectotype vaccination strategy against chicken infectious bronchitis

SCIENTIFIC DISCUSSION

Rabies virus-like particles expressed in HEK293 cells

CevaC Mass L THe Ceva Mass solution

Medical Virology. Herpesviruses, Orthomyxoviruses, and Retro virus. - Herpesviruses Structure & Composition: Herpesviruses

I. Lines of Defense Pathogen: Table 1: Types of Immune Mechanisms. Table 2: Innate Immunity: First Lines of Defense

DURATION OF IMMUNITY OF LIVE VACCINE CEVAC S.

Rama Nada. - Malik

5/6/17. Diseases. Disease. Pathogens. Domain Bacteria Characteristics. Bacteria Viruses (including HIV) Pathogens are disease-causing organisms

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Chapter 14 Part One Biotechnology and Industry: Microbes at Work

Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them

Size nm m m

7.012 Quiz 3 Answers

Transcription:

The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1

IBV encodes four major structural proteins: the spike protein (S), the phosphorylated nucleo capsid protein (N), the integral membrane protein (M) and the small envelope protein (E). The S protein is initially translated into a precursor glycoprotein that is cleaved post translationally to form two subunits, S1 and S2. 2

3

Vaccination with the purified rs1, rn or rm proteins expressed in Escherichia coli. 12 chickens per group vaccinated by eye drop with the purified proteins at: day of age 2 weeks and 5 weeks. At the age of 44 days all the chickens were challenged with 10 5 EID 50 pathogenic M41. Positive control Vaccination: by eye drop with live H120 vaccine was performed twice: at day of age and at 3 weeks of age. 4

Group No. Vaccine Protein concentration Delivery mode 1. 12 chicks PBS Eye drop 2. 12 chicks H120 1 dose / chicken 2 times 3. rs1 150 g / chicken 12 chickens 3 times 4. rn 150 g / chicken 12 chickens 3 times 5. rm 150 g / chicken 12 chickens 3 times Eye drop Eye drop Eye drop Eye drop 5

Protection. vaccination Average Percent protection Non vaccinated 9% 11% 2 X H120 89% 96% 3 X S1 40% 43% 3 X N 30% 33% 3 X M 10% 6

Systemic humoral response. Antibody titers were measured with a commercial kit (IDEXX) Non of the experimental groups demonstrated positive titers before the challenge (Cutoff 397). H120 rs1 rn rm Non vaccinated 640 390 320 211 160 7

9 days post challenge, High antibody titers were observed H120 rs1 rn rm nonvaccinat ed 1720 1260 1450 970 940 8

On the day of challenge HI titers were: H120 rs1 rn rm Non vaccinated 1:360 1:600 1:48 1:1 0 HI titers 9 days post challenge: H120 rs1 rn rm Non vaccinated 1:1024 1:1200 1:240 1:228 1:256 9

IgA and IgG titers were measured by specific ELISA in tracheal washes. Results are given in O.D. 620nm values. IgA H120 S1 N M Non Vaccinated At 14 days of age At 40 days of age At 49 days of age At 58 days of age 0.01 0.08 0.08 0.18 0.13 0.22 0.20 0.16 0.15 0.12 0.54 0.26 0.30 0.16 0.13 0.80 0.70 0.58 0.28 0.24 10

IgG H120 S1 N M Nonvaccinated At 14 days of age At 35 days of age At 49 days of age At 58 days of age 0.02 0.10 0.06 0.05 0.03 0.14 0.18 0.08 0.05 0.03 0.16 0.20 0.16 0.05 0.03 0.38 0.28 0.24 0.15 0.32 11

Summing up the immune response of chickens to rs1 glycoprotein expressed in Escherichia coli as a vaccine applied by eye drops. Challenge 3 weeks after the third vaccination: low protection (40%) as compared to 90% of 2 vaccinations with H120. IBV antibody titers measured by commercial ELISA kit (IDEXX) before challenge were below detectable level. But Nine days post challenge H120= 1720 rs1= 1260 12

Three weeks after the third vaccination a high HI antibody titer was found (1:600) while the titer of the group vaccinated twice with H120 (1:360). rs1 vaccination resulted in virus specific IgA (OD 620 = 0.25) and IgG titers (OD 620 = 0.20) in tracheal washes. After challenge these titers were increased. both lower than the titers resulted from H120 vaccination 13

Summing up the immune response of chickens to rn protein expressed in Escherichia coli as a vaccine applied by eye drops. Challenge 3 weeks after the third vaccination resulted in low protection of 30% IBV antibody titers measured by commercial ELISA kit (IDEXX) of all the groups before challenge were below detection level. Nine days post challenge H120= 1720 rn= 1450 14

rn Three times rn protein vaccination resulted in IgA level of OD 620 = 0.30 and low IgG titers (OD 620 = 0.16) in tracheal washes. The immune responses to the purified M protein were low. Protein M play a negligible role in the humoral immune response to IBV 15

Update literature review S1 16

Already in 1994 Ignjatovic and Galli (Arch.Virol. 138:117) produced the S1, N, and Mproteins from IBV N1/62 which was nephropathogenic and used them for immunization of chickens. Multiple immunization were necessary for induction of an antibody response. Neither the Nnor the Mantigen induced protection to a virulent challenge after 4 immunizations. 17

Zhang et al., (2012. Virology Journal 2012: 9:85) A recombinant Marek s disease virus that expresses the S1 gene from the QX like IBV inserted into the genome of the CVI1988/Rispens strain of MDV. SPF chickens that were vaccinated at day old with rmdv S1 found to have a low level of antibody response until 4 weeks post vaccination, but after IBV challenge at 4 weeks of age, the antibody level increased more rapidly compared with the control group. The chickens were protected when challenged with the QX like IBV 18

Zhang et al., 2014 (Vaccine 32:664 670) produced a modified baculovirus mediating transgene expressing the S1 glycoprotein of M41 strain on the baculovirus envelope under the control of a mammalian promoter, designated BacMam virus. 19

This product elicited stronger humoral and cell mediated immune responses and showed a greater capacity to induce cytotoxic T lymphocyte responses. Using this product as a vaccine, it resulted in 83% protection following challenge with IBV M41. 20

Lv et al., 2014. (J. Vet. Sci. 15:209) developed a chimeric virus like particle (VLP). The VLP was composed of matrix protein from avian influenza (H5N1) and fusion protein neuraminidase/spike protein S1. They immunized i.m. mice and chicken The chimeric VLPs induced significantly higher neutralization antibody level than inactivated H120 virus in SPF chickens. 21

Liu et al 2013 (vaccine 31:5524-5530) inserted M and S proteins to Baculovirus in Sf9 cells and assembled IBV VLPs. The generated VLPs induced, 28 days post vaccination humoral immune responses in a level comparable to that of inactivated IBV vaccine and elicited significantly higher cellular immune responses (Elispot of interferon and IL-4 secreting spleen cells) than the inactivated vaccine. 22

Falchieri et al., 2013 (Vaccine 31:2565 2571) Expressed either S1 or N genes of IBV in subtype A of AMPV. A bivalent recombinant was also prepared Day old chicks were vaccinated by eye drop, induced protection against virulent IBV QX challenge 3 weeks later, as assessed by tracheal cilia activity. Nonetheless no sero conversion nor major recombinant tracheal replication (by real time RT PCR) in the rampv/ibv vaccinated chicks could be observed. 23

Toro et al., 2014 (Avian Diseases 58:211) studied the protective properties of S1 proteins of 3 distinct ArkDPI vaccine subpopulations, expressed in a recombinant adenovirus vector which become selected in chickens after vaccination, and designated as C2, C4 and C5. Population C4 showed high prevalence after vaccination, C5 is rarely seen 24

best protection was conferred by S1.C2 followed by S1.C5. Chicken vaccinated with S1.C4 were indistinguishable from unvaccinated / challenged control chickens. These results were also confirmed by the differences in tears viral load, IBV specific IgG and IgA lymphocytes responses. The AA sequences are responsible to these differences 25

S2 protein. S2 remains largely unexposed to the immune system during natural infection. Speculatively overexposure to S2 likely induce an increase in B and T cells bearing receptors interacting with epitopes on the S2. 26

Toro et al., 2014 (Avian Diseases 58:83 89) developed Newcastle disease virus (LaSota) expressing IBV S2 gene. IBV heterotypic protection was assessed using a prime boost approach with a commercial attenuated Mass type vaccine. Their results demonstrated that priming with IBV S2, overexposing the chicken immune system with S2, followed by boost with whole virus protects chickens against IBV. Regarding incidence of detection of challenge IBV RNA in the trachea, viral RNA was detected in 50% of rls/ibv.s2 + Mass vaccination while chicken vaccinated twice with Mass or unvaccinated challenged control showed 84% and 90% incidence of IBV RNA detection COST FA1207 in Budapest the meeting trachea. 27

N protein The corona virus nucleocapsid (N) protein, an virus internal protein, plays a multifunctional role in the virus life cycle, from regulation of replication and transcription and genome packaging to modulation of host processes. 28

The N protein is expressed abundantly during infections. Thus it is a target protein when designing infectious bronchitis vaccine, and frequent target of diagnostic applications. Fang Yan et al., 2013 J. Vet. Sci. 14:53 60) Chickens immunized with pvax1 16N had a significant high level of IBV specific cellular proliferation and T lymphocytes 29

The N protein can induce high titers of crossreactive antibodies and cell mediated immunity, which protects chickens from acute infections. 30

M protein. The M protein is associated with virus assembly. The M glycoprotein can induce the production of detectable antibodies and delayed hypersensitivity responses 31

Fang Yan et al., 2013 (J. Vet. Sci. 14:53 60) constructed 4 plasmids (DNA ) expressing the S1, N and M proteins of a virulent IBV strain (pvax1 16S1, pvax1 16N, pvax1 16M and pvax1 16S1/M/N). Chickens were immunized monovalently with each individual plasmid or multivalent with combination of the three different plasmids, followed by boosting with an inactivated IBV before being challenged with virulent IBV. All Three IBV proteins have their own unique and important role in eliciting IBV immune responses. 32

Vaccination with pvax1 16M alone provoke the weakest immune response demonstrated by the lowest antibody titers, pvax1 16N moderate, and pvax1 16S1 the highest. Chickens immunized with pvax1 16N had a significant higher level of IBV specific cellular proliferation and T lymphocytes than birds immunized with pvax1 16M or pvax1 16S1. The challenge assay also proved that the DNA vaccine targeting the N protein is more effective. 33

Combination of S1, M and N genes provide stronger protection against IBV. Administration of the DNA vaccine resulted in effective cellular immunization and promote virus clearance. 34

Conclusions. S1 is the most important IBV protein, producing moderate humoral immune response but a good protection. S2 protein play some role in the humoral immune response to IBV The role of the N protein should not be overlooked as it stimulate cell mediated response. The role of the M protein is not well defined. 35

Chickens that received a combination of the three viral proteins mounted a stronger immune responses than the birds immunized with each of the proteins alone. 36

37